-
公开(公告)号：US11492594B2
公开(公告)日：2022-11-08
申请号：US16814186
申请日：2020-03-10
摘要： The present invention provides a new method for producing Engineered Heart Muscle (EHM) under chemically fully defined conditions all compatible with GMP regulations. The resulting human myocardium generates force and shows typical heart muscle properties.
-
2.发明申请公开(公告)号：US20190300858A1
公开(公告)日：2019-10-03
申请号：US16416580
申请日：2019-05-20
IPC分类号： C12N5/077
摘要： The present invention is directed to a method for producing bioengineered heart muscle (BHM) from pluripotent stem cells, generally comprising the steps of inducing mesoderm differentiation, cardiac differentiation, and cardiac maturation by directed tissue formation. The method is a robust, serum-free and reproducible way to produce BHM for multiple applications, and is applicable to multiple pluripotent stem cell lines. The present invention is also directed to the BHM produced by the method disclosed herein, as well as to uses of said BHM in pharmacologic and toxicity screenings, and its use in medicine.
-
公开(公告)号：US20180311212A1
公开(公告)日：2018-11-01
申请号：US15771430
申请日：2016-10-28
发明人： Lutz F. TIETZE , Kamala PENCHALAIAH
IPC分类号： A61K31/403 , A61K47/68 , A61K39/395 , A61P35/00
CPC分类号： A61K47/6803 , A61K47/6889 , C07D209/60 , C07H17/02
摘要： A first aspect of the invention relates to novel compounds and more precisely to novel bifunctional prodrugs and drugs. An additional aspect of the invention relates to antibody compound conjugates, wherein the compound is a claimed compound, and to pharmaceutical compositions containing the compound or antibody compound conjugate. The invention lastly relates to the use of this compound or antibody compound conjugates according to the invention in order to treat tumour diseases, particularly in mammals.
-
公开(公告)号：US20180250284A1
公开(公告)日：2018-09-06
申请号：US15758098
申请日：2016-09-08
申请人： GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN , TEVA PHARMACEUTICAL INDUSTRIES LTD.
IPC分类号： A61K31/4704 , A61K9/00
CPC分类号： A61K31/4704 , A61K9/0053 , C07D217/26
摘要： The present invention relates in a first aspect to compounds for use in the treatment of leukodystrophy whereby these compounds are quinoline derivatives, e.g. laquinimod. In a further aspect, the present invention relates to methods for the treatment of Leukodystrophy, in particular, peroxisomal disorders including Zellweger syndrome.
-
公开(公告)号：US20230279357A1
公开(公告)日：2023-09-07
申请号：US18017922
申请日：2021-07-28
CPC分类号： C12N5/0657 , C12N5/0697 , C12N2500/32 , C12N2500/90 , C12N2501/115 , C12N2501/155 , C12N2501/16 , C12N2501/165 , C12N2501/33 , C12N2501/727 , C12N2503/02 , C12N2506/13 , C12N2506/45 , C12N2533/52
摘要： The application describes a method for producing a population of cardiac stromal cells from pluripotent stem cells. Specifically, the method relates to (i) inducing epithelial-mesenchymal transition of pluripotent stem cell derived epicardial cells and (ii) amplifying the number of cardiac stromal cells in serum-free conditions. These cardiac stromal cells can be mass produced according to the described method and said cells maintain the expression of CD90, CD73 and CD44 in at least 80% of the cardiac stromal cells. Furthermore, the application relates to a population of cardiac stromal cells, which are pluripotent stem cells derived and wherein at least 80% of the cardiac stromal cells express CD90, CD73 and CD44. Said cardiac stromal form the basis for several in vitro and in vivo applications such as the production of engineered organ tissue and the support of, for example, heart repair. Also, a serum- free culture medium for the amplification of cardiac stromal cells is provided herein.
-
公开(公告)号：US20230256646A1
公开(公告)日：2023-08-17
申请号：US18024751
申请日：2021-09-08
发明人： Holger Militz
CPC分类号： B27K3/50 , B27K3/0292 , B27K3/15 , B27K5/001
摘要： Production method for modified lignocellulose materials. The present invention relates to a production method for modified lignocellulose materials, comprising the impregnation of a lignocellulose material, especially wood, with a solution of an acid and an alcohol as well as treatment of the material with superheated steam at elevated temperatures.
-
公开(公告)号：US20230203140A9
公开(公告)日：2023-06-29
申请号：US17282592
申请日：2019-10-02
发明人： Thomas BAYER , Preeti BAKRANIA , Sarah DAVIES , Alex BROWN , Chido MPAMHANGA , David MATTHEWS , Mark CARR , Gareth HALL
CPC分类号： C07K16/18 , A61P25/28 , C07K2317/24 , C07K2317/567 , A61K2039/505
摘要： The present invention relates to humanised antibodies that bind amyloid peptides, which antibodies comprise mutations in the heavy chain and/or light chain variable domains, which mutations improve the binding activity. The antibodies may be useful in the treatment of Alzheimer's disease (AD).
-
公开(公告)号：US11518991B2
公开(公告)日：2022-12-06
申请号：US16488131
申请日：2018-02-26
发明人： Elisabeth Zeisberg , Xingbo Xu
IPC分类号： C12N15/10 , C12N15/113 , C12N9/02 , C12N9/22 , C12N15/67
摘要： A method for re-expression of hypermethylated RASAL1, hypermethylated LRFN2, and hypermethylated KLOTHO based on an inactivated CRISPR-based system and a DNA dioxygenase as well as a gRNA guiding the construct to the RASAL1, LRFN2, and KLOTHO gene for demethylation of hypermethylated RASAL1, hypermethylated LRFN2, and hypermethylated KLOTHO, in particular, hypermethylated RASAL1, LRFN2, and KLOTHO promoter, thus, allowing re-expression of RASAL1, LRFN2, and KLOTHO for the treatment of fibrosis, cancer or neuronal disorders in a subject is provided. A kit of parts for allowing re-expression of hypermethylated RASAL1, hypermethylated LRFN2, and hypermethylated KLOTHO in a subject, a vector or vector system, and nucleic acid constructs are also provided.
-
公开(公告)号：US20210261519A1
公开(公告)日：2021-08-26
申请号：US17254774
申请日：2019-07-11
IPC分类号： C07D333/76 , C07B43/08 , C07B37/02
摘要： The present invention describes a new alkynylation and cyanation agent, as well as its preparation and use to introduce nitrile (cyano) or alkyne groups into chemical target molecules by means of an electrophilic reaction. To enable an electrophilic reaction, the chemical backbone of dibenzothiophene was used.
-
公开(公告)号：US20210023242A1
公开(公告)日：2021-01-28
申请号：US16967917
申请日：2019-02-21
发明人： Tobias MOSER , Thomas WEBER , Vladan RANKOVIC , Christian VOGL
摘要： The present invention relates to a viral vector, especially an adeno-associated virus (AAV) vector, and the use thereof in the gene-therapy treatment of hearing impairment, especially of hearing impairment based on one or more mutations in the otoferlin gene (OTOF).
-
-
-
-
-
-
-
-
-
搜索结果
47 条记录 (耗时 0.021 秒)
